Publications by authors named "Catherine Milch"

Claim this Profile
E
Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme.
Silvio Danese, Axel Dignass, Katsuyoshi Matsuoka, Marc Ferrante, Millie Long, Catherine Milch

J Crohns Colitis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies.
Taku Kobayashi, Katsuyoshi Matsuoka, Mamoru Watanabe, Tadakazu Hisamatsu, Fumihito Hirai, Catherine Milch

Intest Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52.
Travis Johnson, Boyd Steere, Pengyue Zhang, Yong Zang, Richard Higgs, Catherine Milch

Clin Transl Gastroenterol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Geert D'Haens, Marla Dubinsky, Taku Kobayashi, Peter M Irving, Stefanie Howaldt, Catherine Milch

N Engl J Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials.
Asit Parikh, Kristin Stephens, Eugene Major, Irving Fox, Catherine Milch

Drug Saf· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
Maria Rosario, Nathanael L Dirks, Catherine Milch, Asit Parikh, Michael Bargfrede

Clin Pharmacokinet· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Jean-Frédéric Colombel, Bruce E Sands, Paul Rutgeerts, William Sandborn, Silvio Danese, Catherine Milch

Gut· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
Gerald S Falchook, Xiaofei Zhou, Karthik Venkatakrishnan, Razelle Kurzrock, Devalingam Mahalingam, Catherine Milch

Drugs R D· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
Gerald S Falchook, Karthik Venkatakrishnan, John Sarantopoulos, Razelle Kurzrock, Alain C Mita, Catherine Milch

Int J Clin Pharmacol Ther· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Bruce E Sands, Brian G Feagan, Paul Rutgeerts, Jean-Frédéric Colombel, William J Sandborn, Catherine Milch

Gastroenterology· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype.
Catherine Milch, Tim Wyant, Jing Xu, Asit Parikh, Whitney Kent

J Neuroimmunol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, Catherine Milch

N Engl J Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab as induction and maintenance therapy for Crohn's disease.
William J Sandborn, Brian G Feagan, Paul Rutgeerts, Stephen Hanauer, Jean-Frédéric Colombel, Catherine Milch

N Engl J Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in triage thresholds for patients presenting with possible acute coronary syndromes: more than meets the eye.
Catherine E Milch, David M Kent, Robin Ruthazer, J Hector Pope, Thomas P Aufderheide

J Investig Med· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Voluntary electronic reporting of medical errors and adverse events. An analysis of 92,547 reports from 26 acute care hospitals.
Catherine E Milch, Deeb N Salem, Stephen G Pauker, Thomas G Lundquist, Sanjaya Kumar

J Gen Intern Med· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoking cessation in primary care: a clinical effectiveness trial of two simple interventions.
Catherine E Milch, Janet M Edmunson, Joni R Beshansky, John L Griffith, Harry P Selker

Prev Med· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis